EN PL

EMA: Draft guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia

28.03.2013
This guideline describes the information on the clinical development to be documented when an application for a marketing authorisation for a medicinal product is made for the treatment of chronic primary immune thrombocytopenia. The purpose of this guidance is to provide a harmonised regulatory approach that will lead to a consistent assessment of products by regulators and set clear standards for industry.